Researchers at MIT have developed a new AI model capable of assessing a patient’s risk of pancreatic cancer, reports Erez Meltzer for Forbes. “The model could potentially expand the group of patients who can benefit from early pancreatic cancer screening from 10% to 35%,” explains Meltzer. “These kinds of predictive capabilities open new avenues for preventive care.”
MIT scientists have shown a simple paper-strip test can detect the flu and identify the specific strain, which could prove useful in improving outbreak response and infection care, writes Dennis Thompson for HealthDay. Jon Arizti-Sanz PhD ’24 says “being able to tease apart what strain or subtype of influenza is infecting a patient has repercussions both for treating them and public health interventions.”
Researchers from MIT and elsewhere have developed an AI model that is capable of identifying 3 ½ times more people who are at high-risk for developing pancreatic cancer than current standards, reports Felice J. Freyer for The Boston Globe. “This work has the potential to enlarge the group of pancreatic cancer patients who can benefit from screening from 10 percent to 35 percent,” explains Freyer. “The group hopes its model will eventually help detect risk of other hard-to-find cancers, like ovarian.”
Forbes contributor William Haseltine spotlights how MIT researchers developed a biosensor ingestible capsule that can gather and transmit information on a patient’s condition to a physician. Haseltine notes that “aside from respiratory and heart rate monitoring, future applications for the pill could come from alterations in its design, leading to other avenues of health monitoring. These may include digestive health, blood sugar monitoring and cancer cell detection.”
Researchers from MIT and elsewhere are developing an electronic pill that can “measure heart rate, breathing rate and core temperature – from inside a human stomach,” reports Celia Ford for Wired. “We have a solution that’s relatively simple and enables access broadly,” says Prof. Giovanni. “I think that can be really transformative.”
Researchers from MIT and elsewhere have developed a swallowable “technopill” that can monitor vital signs from inside the body, reports Dennis Thompson for HealthDay. “The ability to facilitate diagnosis and monitor many conditions without having to go into a hospital can provide patients with easier access to healthcare and support treatment,” says Prof. Giovanni Traverso.
A team including researchers from MIT have developed a new ingestible ‘smart capsule’ that uses a patient’s vital signs to detect sleep disorders or opioid overdoses. “The findings suggest that the ingestible was able to measure health metrics on par with medical-grade diagnostic equipment at the sleep center,” writes Malak Saleh for Engadget.
Prof. Gio Traverso speaks with Lizzy Lawler at STAT about a new ingestible sensor that monitors a person’s heart and breathing rates to detect sleep disorders. “The vision for sleep evaluation is the ability to detect these events wherever you are in the nation, and not having to go to a sleep lab and an inpatient setting,” says Traverso.
New Scientist reporter Alice Klein writes that MIT researchers have developed an ingestible electronic device that “can measure your breathing and heart rate from inside your gut [and] could potentially diagnose sleep apnea and even detect opioid overdoses.” The device could one day allow “people to be assessed for sleep apnea wirelessly and cheaply while at home.”
Researchers at MIT and elsewhere have developed a swallowable electronic capsule that can be used to help diagnose sleep apnea and other sleep disorders, reports Ian Randall for Newsweek. “Conventional laboratory and home sleep studies require the patient to be attached to many different sensors,” says Prof. Giovanni Traverso. “As you can imagine, trying to sleep with all of this machinery can be challenging. [The] ingestible capsule just requires that the patient swallow the vitamin-sized pill. It's easy and unobtrusive and can accurately measure both respiratory rate and heart rate while the patient sleeps."
Researchers from MIT and Massachusetts General Hospital have developed “Sybil,” an AI tool that can detect the risk of a patient developing lung cancer within six years, reports Mary Kekatos for ABC News. “Sybil was trained on low-dose chest computer tomography scans, which is recommended for those between ages 50 and 80 who either have a significant history of smoking or currently smoke,” explains Kekatos.
Prof. Regina Barzilay speaks with Nicole Estephan of WCVB-TV’s Chronicle about her work developing new AI systems that could be used to help diagnose breast and lung cancer before the cancers are detectable to the human eye.
Soledad O’Brien spotlights how researchers from MIT and Massachusetts General Hospital developed a new artificial intelligence tool, called Sybil, that an accurately predict a patient’s risk of developing lung cancer. “Sybil predicted with 86 to 94 percent accuracy whether a patient would develop lung cancer within a year,” says O’Brien.
Researchers at MIT have developed a new nanoparticle sensor that can detect cancerous proteins through a simple urine test. “The researchers designed the tests to be done on a strip of paper, similar to the at-home COVID tests everyone became familiar with during the pandemic,” writes Lambert. “They hope to make it as affordable and accessible to as many patients as possible.”
NBC News highlights how researchers from MIT and MGH have developed a new AI tool, called Sybil, that can “accurately predict whether a person will develop lung cancer in the next year 86% to 94% of the time.” NBC News notes that according to experts, the tool "could be a leap forward in the early detection of lung cancer.”